DTaP Vaccination Schedule and Contraindications
DTaP is administered as a 5-dose series at ages 2,4,6,15-18 months, and 4-6 years, and is only indicated for children under 7 years of age. 1
Routine Vaccination Schedule
Primary Series (Ages 2 months - 6 years)
The standard DTaP schedule consists of five doses administered at specific ages to ensure optimal protection against diphtheria, tetanus, and pertussis 1:
- Dose 1: 2 months (minimum age: 6 weeks)
- Dose 2: 4 months
- Dose 3: 6 months
- Dose 4: 15-18 months (first booster)
- Dose 5: 4-6 years (second booster)
Critical Timing Rules
The fourth dose must be administered at least 6 months after the third dose and the child must be at least 12 months old. However, a fourth dose given at least 4 months after the third dose is considered valid if the child is ≥12 months 1.
A fifth dose is not necessary if the fourth dose was administered at age ≥4 years 1.
Administration Details
- Dose: 0.5 mL intramuscularly 1
- Site: Anterolateral thigh for children ≤2 years; deltoid muscle for children ≥3 years 1
- Interchangeability: Any licensed DTaP product may be used to complete the series, though using the same product for all doses is preferred when feasible 1
Age Restrictions and Inadvertent Administration
DTaP is NOT indicated for persons aged ≥7 years 1. This is a critical distinction that prevents common errors.
If DTaP is Given Inadvertently:
Ages 7-10 years (fully vaccinated):
- Count the dose as the adolescent Tdap dose 1
Ages 7-10 years (undervaccinated):
- Count as the Tdap dose in the catch-up series
- Still give adolescent Tdap booster at ages 11-12 years 1
Age ≥11 years:
- Count as the Tdap dose
- Do NOT give an additional Tdap dose 1
Contraindications
Absolute contraindications to DTaP include 1:
- Severe allergic reaction (anaphylaxis) after a previous dose or to a vaccine component
- Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within 7 days of a previous dose of pertussis-containing vaccine, not attributable to another identifiable cause
Precautions (Defer Vaccination)
Providers should evaluate risks versus benefits when the following precautions are present 1:
- Progressive or unstable neurologic disorder
- Uncontrolled seizures
- Progressive encephalopathy
- Moderate or severe acute illness with or without fever
For children with a contraindication specific to the pertussis component, use DT (diphtheria-tetanus toxoids) instead 1, 2. DT is licensed for children up to age 7 years and is administered as 0.5 mL intramuscularly 1.
Common Pitfalls to Avoid
Do not use DTaP in anyone ≥7 years old - this is the most common error. Use Tdap instead for adolescents and adults.
Do not give the fourth dose before 12 months of age, even if 6 months have elapsed since the third dose 1.
Do not confuse DTaP with Tdap - DTaP has higher diphtheria and pertussis antigen content and is only for young children.
Observe patients for 15 minutes post-vaccination, especially adolescents, due to syncope risk 1.
Do not delay vaccination due to minor illness - mild upper respiratory infections or low-grade fever are not contraindications 1.
Special Considerations
Minimum Intervals During Outbreaks
During pertussis outbreaks, minimum interval schedules (4 weeks between doses 1-3) may be used to accelerate protection, which has been shown to improve overall vaccination rates 3.
Undervaccination Risk
Undervaccination (receiving fewer than recommended doses) significantly increases pertussis risk with adjusted relative risks of 4.8 for the primary series, 3.2 for the first booster, and 4.6 for the second booster 4. Short delays in timing are less critical than ensuring all doses are eventually administered.
Pregnancy Considerations
While this question focuses on DTaP for children, note that pregnant women should receive Tdap (not DTaP) during each pregnancy at 27-36 weeks' gestation to protect newborns before their first DTaP dose 1, 5.